Inhibikase Therapeutics announced that it has filed a Request for Withdrawal with the U.S. Securities and Exchange Commission with respect to the withdrawal of the Company’s Registration Statement on Form S-1 that it filed with the SEC originally on April 19, 2024. The Registration Statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering described in the Registration Statement.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IKT:
- Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
- IKT Earnings this Week: How Will it Perform?
- Inhibikase Therapeutics announces final pre-IND meeting outcomes for IkT-001Pro
- Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
- Inhibikase Therapeutics Faces Legal Dispute Amid Clinical Trials